FLSM
SNDX icon

Frazier Life Sciences Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Frazier Life Sciences Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-600,000
Closed -$1.57M – 56
2023
Q3 		$1.57M Buy
+600,000
New +$11.3M 0.1% 49

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Frazier Life Sciences Management's SNDX Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 600,000 shares — an estimated $8.71M sold.

Frazier Life Sciences Management first reported a position in SNDX in Q1 2022 and held it in 7 quarters. The position peaked at $94.4M in Q4 2022. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Frazier Life Sciences Management reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 600,000 Syndax Pharmaceuticals shares in Q4 2023, an estimated $8.71M.
  • Frazier Life Sciences Management first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Frazier Life Sciences Management's Syndax Pharmaceuticals position peaked at $94.4M in Q4 2022.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.